Iluvien

A NICE Technology Appraisal

Starring Alison Richards as Patient Expert.
What happens during a Technology Appraisal?

• NICE learns all about the technology being appraised through asking consultees questions. Consultees include the manufacturer, an evidence review group, commissioners of NHS services, The Royal College of Ophthalmologists and patient groups.

• Having considered all the information gathered, NICE calculates whether benefit to patients is worth the cost.

• When recommendation occurs, NICE indicates the criteria of disease progression/severity which must be met before the therapy is used and criteria for stopping it.
What do consultees do?

• The pharmaceutical company present the results of their trials and their analysis of benefit to patients.

• Consultees comment on what makes the technology helpful in clinical practice, what the patient body and carers feel about it and any drawbacks or reservations they have identified.

• Consultees give their arguments concerning where the technology may be placed within existing clinical guidelines and compare the benefit of this technology with other technologies routinely funded, and individually funded, (IFR) in current clinical practice.
Decision making

• Everyone reads documents supplied by NICE prior to a meeting at which NICE summarises arguments made and all consultees have the opportunity to speak, ask and answer questions.

• A decision making meeting is held within NICE. When the technology is deemed value for money, a draft proposal is circulated to consultees for comment. Amendments may be made.

• When recommendation occurs, NICE indicates the criteria of disease progression/severity which must be met before the therapy is used and criteria for stopping treatment.
OV & PINGU
What we’ll do as a Stake holder consultee.

- Nominate a patient expert – Alison.
- Let NICE know what it’s like to live with uveitis or care for someone with it.
- Present our views about existing treatments and QoL when using them.
- Tell NICE what we think about Iluvien – how it will improve our vision, our QoL and when we think it should be offered to us, as well as our attitude to the drawbacks of cataract and the potential for raised ocular pressure.
Patient Experts

• A patient’s good experience of the treatment is proof that the cost of the treatment justifies its expense from a patient’s perspective.

• They give a written account of their experience of the disease to describe: how their condition affects their lives; treatments they’ve received and what they wanted as outcomes from those treatments.

• They make clear the benefit from this new treatment on their condition and the change it has made to their quality of life.

• They may speak for all of us when stakeholders meet with NICE.